

■ SCION CARDIO-VASCULAR ANNOUNCES AGREEMENT WITH MEDTRONIC FOR DISTRIBUTION OF THE CLO-SUR P.A.D., AN INNOVATIVE DEVICE USED FOR RAPID BLEEDING CONTROL AFTER CATHETERIZATION

Medtronic Makes Minority Equity Investment in Scion Cardio-Vascular.

MIAMI, Florida, September 9, 2002 - Scion Cardio-Vascular, Inc. today announced that Medtronic, Inc. (NYSE: MDT) has obtained exclusive rights to distribute Scion Cardio-Vascular's revolutionary Clo-Sur P.A.D.™. In addition, Medtronic has made a minority equity investment in Scion Cardio-Vascular.

The Clo-Sur P.A.D.™, manufactured by Scion Cardio-Vascular, is a groundbreaking, non-invasive device used for rapid control of bleeding associated with all vascular access sites. The agreement with Medtronic is limited to application of the device for the rapid control of bleeding associated with catheter removal following a catheterization procedure such as coronary stenting, as well as other minimally invasive procedures. For the more than 5.8 million Americans each year who undergo angioplasties, cardiac catheterizations, PTCA, stenting and other minimally invasive procedures, the Clo-Sur P.A.D. represents a dramatic step forward in the healing process.

The vascular puncture hemostasis market worldwide is expected to reach \$330 million in 2002 and is projected to exceed \$500 million as the number of catheterization procedures increases. Scion Cardio-Vascular's Clo-Sur P.A.D.™. employs a foam pad technology utilizing the company's proprietary polymer Polyprolate™ to stop the bleeding at the puncture site. The device is water soluble to allow easy removal.

Scion Cardio-Vascular has received FDA clearance to market the *Clo-Sur P.A.D.™* in the United States and expects to be granted (CE) Marking approval in September to market the device in Europe. The Clo-Sur P.A.D.™ has been available for sale in the U.S. since December 2001 and has been very well received by U.S. hospitals and clinicians.

"In our experience with over 1,000 Clo-Sur P.A.D.s, the device has proven to be safe, effective and easy to use, and most important, it is non-invasive," said Barry Alter, M.D., of Memorial Regional Hospital, Hollywood, Florida.

"We have seen our sales grow dramatically in the U.S.," said George Golik, Scion Cardio-Vascular President. *"Medtronic has an impeccable reputation and tremendous market coverage. We expect sales to accelerate even faster as a result of this new partnership."*

"We are a company committed to providing a complete range of advanced products and services in the catheterization lab," said William Hawkins, President of Medtronic Vascular. *"We are pleased now to be able to offer this safe and cost-effective device for clinicians to complete their procedures."*

Scion Cardio-Vascular, Inc., a privately held company located in Miami, Florida, is dedicated to bringing creativity and innovation to the interventional cardiology and radiology markets. Scion Cardio-Vascular offers simple, cost effective technology for use in minimally invasive surgical procedures. Its Internet address is www.scioncv.com.

Medtronic, Inc., headquartered in Minneapolis, is the world's leading medical technology company, providing lifelong solutions for people with chronic disease. Medtronic Vascular, formerly Arterial Vascular Engineering, is headquartered in Santa Rosa, CA. Its Internet address is www.medtronicave.com.